Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,207

Document Document Title
WO/2022/106574A1
Object of the present invention is an improved process for the preparation of Trenbolone (I-b) and/or Trenbolone Acetate (I-a) comprising the reaction of the compound of formula (II): wherein R is H or Ac; with an oxidant agent in presen...  
WO/2022/106566A1
Object of the present invention is an improved process for the preparation of Trenbolone Acetate of formula (I) having irregular hexagon plates crystal habit and/or a median value (D50) of the particle size distribution comprised in the ...  
WO/2022/055542A1
Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkag...  
WO/2022/006145A1
The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such co...  
WO/2021/262836A1
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...  
WO/2021/252761A2
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...  
WO/2021/252459A1
The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition ...  
WO/2021/237371A1
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected ...  
WO/2021/226465A1
The present disclosure relates to polycyclic (e.g., tetracyclic) glucocorticoid receptor (GR) modulators, synthetic methods for preparing such GR modulators, and methods of using such GR modulators to treat a glucocorticoid-dependent con...  
WO/2021/175751A1
The present disclosure generally provides 11-oxo-cucurbitane compounds, including various glycosides, and the use of such compounds and related compounds as flavor modifiers. In some aspects, the disclosure provides compositions that inc...  
WO/2021/167008A1
This method for producing an aromatic astatine compound comprises reacting aromatic iodonium ylide with astatine to produce an aromatic astatine compound.  
WO/2021/104503A1
Disclosed is a method for preparing β-carbonyl sulfone. The method comprises: by taking an α-carbonyl diazo compound and sodium arylsulfinate as reaction substrates, cheap silver nitrate as an optimal catalyst, 1,10-phenanthroline as a...  
WO/2021/080880A1
N-methyl-d-aspartate receptors (NMDAR) and/or potentiating y-aminobutyric acid receptors (GABAAR) agents and uses thereof are described. Uses of these agents include methods of treating or preventing various psychiatric diseases, disorde...  
WO/2021/075860A1
The present invention relates to novel 2-Methoxyestradiol derivatives and their medical use. In particular, the novel derivatives of the present invention are useful for the treatment or prevention of liver or lung fibrosis. Accordingly,...  
WO/2021/069570A1
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...  
WO/2021/058716A1
The present invention relates to a process for preparing (15α,16α,17β)-Estra-1,3,5(10)-triene-3,15,16,17-tetrol, also known as Estetrol, having the formula shown below: (I)  
WO/2021/044302A1
The invention relates to the preparation of estetrol of formula (I), derivatives thereof protected at positions 3,15α,16α,17β of general formula (III), and 3-hydroxy derivatives thereof protected at positions 15α,16α,17β of general...  
WO/2021/012673A1
Disclosed is a method for preparing trenbolone acetate, same belonging to the technical fields of preparation and processing of hormone drugs. According to the method, 3-ethylenedioxy-estra-[delta]5,10, [delta]9,11-dien-17-one is used as...  
WO/2020/264512A1
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...  
WO/2020/264495A1
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...  
WO/2020/243488A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...  
WO/2020/223174A1
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cel...  
WO/2020/187965A1
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.  
WO/2020/180661A1
This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosur...  
WO/2020/176843A1
The present invention generally relates to new compounds for therapeutic uses. In particular, this disclosure relates to novel tetracyclic compounds useful for treatment of cancer, especially castration resistant prostate cancer. Pharmac...  
WO/2020/132504A1
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...  
WO/2020/118437A1
The present invention relates to new compounds and compositions comprising active ingredient derivatives of testosterone, and novel testosterone derivatives, novel testosterone methods, novel testosterone compositions, novel testosterone...  
WO/2020/104484A1
The present invention relates to the synthesis of N-trifluoromethylcarbonyl compounds starting from isothiocyanates, which can be converted into N-trifluoromethylcarbamoyl fluorides or similar compounds, which later on can be derivatized...  
WO/2020/082065A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...  
WO/2020/077255A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...  
WO/2020/053509A1
The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is n...  
WO/2020/051329A1
The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds...  
WO/2019/186444A1
The present invention relates to liquid formulations of Abiraterone intended for oral administration. The invention provides suspension and emulsion fom1ulations of Abiraterone and process of preparing such formulations. Further, the inv...  
WO/2019/173499A1
Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment w...  
WO/2019/165350A1
The present invention discloses processes for producing normal alpha olefins, such as 1-hexene, 1-octene, 1-decene, and 1-dodecene in a multistep synthesis scheme from another normal alpha olefin. Also disclosed are reactions for convert...  
WO/2019/129182A1
Disclosed is an application of 2β,3α,5α-trihydroxyl androstane-6-ketone and a deuterated compound thereof or pharmaceutically acceptable salts thereof in the preparation of drugs for treating inflammatory reactions of patients. The pr...  
WO/2019/128154A1
Provided is a method for synthesizing the 17-position side chain of a steroid drug, wherein same is characterized in using compound I as a starting material, and the 17-position side chain is synthesized by nucleophilic, esterification, ...  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2019/113494A1
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...  
WO/2019/098179A1
Provided are: a novel internal standard substance that is useful for measuring androgen; a highly selective and sensitive (accurate) method for measuring androgen which is capable of simplifying pretreatment and uses liquid chromatograph...  
WO/2019/070139A1
A new crystalline form of anhydrous 17-β-estradiol (estra-l,3,5(10)-triene-3,17β-diol), method of its preparation and its use have been disclosed.  
WO/2019/024920A1
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, ...  
WO/2018/197296A1
The present invention relates to a process for the synthesis of intermediates of general formula (I): by means of a simultaneous protection and hydrogenation reaction of an intermediate of formula (II), according to the scheme below: Com...  
WO/2018/196883A2
Disclosed is a method for preparing 16β-methyl steroid compound, comprising a methylenation reaction and a hydrogenation reduction reaction. Compared to the prior art, the preparation method of the present invention orientedly synthesiz...  
WO/2018/185783A1
The present invention provides a single pot process for the synthesis of 19-Norethisterone of Formula (I), comprising contacting 19-Norandostene-3,17-dione of Formula–II with a first base, an organic gas/solution and an acid to obtain ...  
WO/2018/127927A1
A system for delivery of drugs, and especially genetic drugs such as siRNA or antisense oligonucleotides (ASO) across biological membranes is provided. It comprises a trans- membrane delivery moiety, energized by the membrane internal el...  
WO/2018/129555A1
A method for the treatment of an individual suffering from non-alcoholic steatohepatitis is provided comprising administering to the individual in need of such treatment an effective amount of a compound according to Formula I: wherein: ...  
WO/2018/112512A1
An efficient and commercial phosphorylation process of a complex alcohol, such as secondary and tertiary alcohols, with P4O10 at high temperatures, and a product obtained by the process.  
WO/2018/039110A1
An estrogen receptor β selective ligand can be a compound according to Structure 1: wherein m is 0, 1, or 2 and R is H, a C1 to C5 alkyl group, vinyl, CF3, CH2CH2F, CH2CHF2, or CH2CF3. A composition (e.g., pharmaceutical or cosmetic com...  
WO/2018/025083A1
The described invention relates to small molecule therapeutic compounds capable of reducing the incidence of intracerebral hemorrhage and brain microhemorrhages identified using zebrafish and mouse models of intracerebral hemorrhage and ...  

Matches 1 - 50 out of 2,207